Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMO | O15229 | 1/20 | 0.45 |
| ▸ | SCN9A | Q15858 | 6/20 | 0.44 |
| ▸ | PTGS2 | P35354 | 9/20 | 0.42 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.41 |
| ▸ | SYK | P43405 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.39 |
| ▸ | ALOX5AP | P20292 | 2/20 | 0.39 |
| ▸ | FEN1 | P39748 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7042025 | 0.92 | PTGS2 (0.53) | KMOSCN9APTGS2PTGS1 | |
| SCHEMBL6723228 | 0.91 | PTGS2 (0.45) | KMOSCN9APTGS2PTGS1CYP2C9 | |
| SCHEMBL7541588 | 0.88 | KMO (0.48) | KMOSCN9APTGS2PTGS1ALOX5AP | |
| SCHEMBL7048301 | 0.86 | PTGS2 (0.50) | KMOSCN9APTGS2PTGS1ALOX5AP | |
| SCHEMBL7044091 | 0.84 | PTGS2 (0.50) | KMOPTGS2PTGS1ALOX5APFEN1 | |
| SCHEMBL6730094 | 0.83 | SCN9A (0.45) | KMOSCN9APTGS2PTGS1CYP2C9 | |
| SCHEMBL7539544 | 0.83 | PTGS2 (0.50) | KMOPTGS2PTGS1SYKALOX5AP | |
| SCHEMBL6746360 | 0.83 | PTGS2 (0.46) | KMOSCN9APTGS2PTGS1CYP2C9 | |
| SCHEMBL7546410 | 0.83 | PTGS2 (0.49) | KMOPTGS2PTGS1SYKALOX5AP | |
| SCHEMBL7548196 | 0.82 | PTGS2 (0.47) | KMOSCN9APTGS2PTGS1ALOX5AP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1296971-A2 | 2-FLUOROBENZENESULFONYL COMPOUNDS FOR THE TREATMENT OF INFLAMMATION | Pharmacia Corporation (US) | 2003-04-02 | — | — | EP | disclosed |
| US-20020183362-A1 | 2-Fluorobenzenesulfonyl compounds for the treatment of inflammation | PHARMACIA CORPORATION | 2002-12-05 | — | — | US | disclosed |
| WO-2001081332-A2 | 2-FLUOROBENZENESULFONYL COMPOUNDS FOR THE TREATMENT OF INFLAMMATION | PHARMACIA CORPORATION (US) | 2001-11-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020183362-A1 | 2-Fluorobenzenesulfonyl compounds for the treatment of inflammation | FPR2, FPR1, PTGES2 | KMO 853/4885SCN9A 4442/4885PTGS2 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.